Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

By Katharine Ellwood-Yen, T. Graeber, John Wongvipat, M. Luisa Iruela-Arispe, Jianfeng Zhang, R. Matusik, G. Thomas, C. Sawyers. Cancer Cell, 2003

813 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f1a3e66c3c72db2c827578e6ae564222f8c821a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pathology and Forensic Medicine

In Pulmonary and Respiratory Medicine

Citations in the corpus

Molecular determinants of resistance to antiandrogen therapy (2004, background): “Newer transgenic or knockout models of mouse prostate cancer may provide an opportunity to address this question in a 'cleaner' experimental syste”
MYC on the Path to Cancer (2012, background): “In each of these models, however, additional mutagenic events are necessary for tumor formation as evidenced by a predictable time delay before the onset of tumors (Beer et al., 2004; Ellwood-Yen et al., 2003; Felsher and Bishop, 1999a; Pelengaris et al., 1999).”
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2007, background): “Recent studies applying microarray technology to human lung, liver, or prostate carcinomas and their respective murine counterparts have reported commonalities [8-10].”
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. (2011, background): “The GEM Cancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc. 583 models of human prostate cancer (PB-MYC and Ptenlox/lox PB-Cre) have been described previously (Ellwood-Yen et al., 2003; Trotman et al., 2003).”
Genetic determinants of cancer metastasis (2007, background): “, and to sort relevant transcriptomic patterns between human and murine prostatic and lung adenocarcinom”
Targeting cancer stem cell pathways for cancer therapy (2020, background): “120 These studies indicate that MYC induces tumorigenesis with the help of other factors.”
Genetics and biology of prostate cancer (2018, background): “The oncogenic role of MYC in prostate cancer has been substantiated in mice engineered to overexpress MYC in the prostate, resulting in PIN with progression to invasive adenocarcinoma (Ellwood-Yen et al. 2003).”
Reflecting on 25 years with MYC (2008, background): “Certainly, the recent recognition of MYC-associated genetic fingerprints in primary human tumours is an exciting developmen”
Autonomic Nerve Development Contributes to Prostate Cancer Progression (2013, methodology): “sympathectomy on tumor progression in Hi-Myc transgenic mice (22).”
Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “…transgenic mice overexpressing human MYC display rapid formation of PIN followed by progression to invasive adenocarcinoma with rare metastases (Ellwood-Yen et al. 2003), while forced expression of MYC is sufficient to immortalize nontumorigenenic human prostate epithelial cells (Gil et al.…”
Role of the TMPRSS2-ERG gene fusion in prostate cancer. (2008, neutral): “2, C-terminal FLAG-tagged) under the control of the modified probasin promoter (ARR2Pb-ERG ) (Figure 1 a ), which drives androgen-regulated transgene expression exclusively Neoplasia Vol. 10, No. 2, 2008 TMPRSS2 – ERGin Prostate Cancer Tomlins et al. in the prostate [23,24].”
LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism (2005, background): “Although Myc may bind overlapping sets of genes under various conditions in different cell types (Fernandez et al., 2003), transcriptional responses to Myc binding differs markedly in a context and cell type-dependent manner (Ellwood-Yen et al., 2003).”